Course co-director: Marlene Gyldmark, Head of Modelling,
Outcomes Research, Statistics and Epidemiology, F. Hoffmann-La
Anne Koldby, Value Demonstration
Manager, F. Hoffmann-La Roche AG
Guillaume Dedet, Technical Officer Health Technology and
Pharmaceuticals, Division of Health Systems and Public Health,
World Health Organization, Regional office for Europe
Adri Tolstrup, Director Public Affairs, Global Market Access Novo
Ulla Kirkegaard Madsen, Danish Health and Medicines Authority,
Pharmacies and Reimbursement
Mette Hammer, Global Market Access Director. HEOR GLP-1 &
Biopharm. Global Marketing. Novo Nordisk A/S
Tove Holm-Larsen, Managing Director, Pharma Evidence
Edith Frénoy, Director Market Access/HTA EFPIA (European Federation
of Pharmaceutical Industries and Associations)
Joshua Ray, head of Health Economics, MORSE, F Hoffmann – La Roche
Linus Jönsson Market access in CNS disorders Vice President,
Medical & Regulatory Sciences, H. Lundbeck A/S Karolinska
Institutet, Stockholm, Sweden
Professor Rafael Bengoa, Former Director of Health Systems (World
Additional speakers may be included.
Saved on the
Master's Programme in Industrial Drug Development - elective
The course is preapproved as an elective in the Master of
Industrial Drug Development (MIND) programme, the Master of
Pharmaceutical Regulatory Affairs (MPRA) programme and Master of
Drug Management (MDM) programme and open for freelance students who
meet the admission criteria.
In the competitive world of pharmaceutical sales, developing a
market access strategy and communicating the value of the brands to
the ‘payers’ is at the top of the agenda. In recent years, the
field of pricing and reimbursement of pharmaceuticals has become
more complex and challenging.
The economic crisis, austerity measures and general demographic
changes (aging population) coupled with newer and more expensive
drugs has contributed to bigger hurdles in securing market access.
Decisions are now increasingly made on cost-effectiveness and
cost-containment rationales, whereas only safety and efficacy
guided the decision to a greater degree years ago.
Although everyone seems to be talking about market access, very few
are able to define it. Who are the new key stakeholders, exactly?
Is it no longer the prescribers that decide which drug a patient
should use? Is market access only about containing costs for the
public budgets or are the benefits for patients and society as
This course will provide insight into the key principles and a
practical understanding of ‘market access’ as it relates to the
pharmaceutical industry. The course starts with an overview of the
key stakeholders and current trends in the global market access of
pharmaceuticals followed by a review of the hot topics, challenges
and relevant issues through a combination of lectures, discussions,
group work, and case studies.
The topics include:
Introduction to market access - marketing
trends, defining global market access for the 21st century, its
importance for optimizing product launches and its implications for
the entire organization.
Core concepts of market access – defining
the concepts, theories and methods relevant for the pharmaceutical
Value generation – the role of clinical
trials, real-world evidence, life-cycle management and health
Stakeholders – who they are, their
perspectives, how and when to engage with ‘payers’.
Health economic aspects of market
access – economic and financial considerations, core
concepts and vocabulary.
Pricing and reimbursement – global vs.
local optimization, reference pricing systems in various
Important decision makers in Germany and the
Trends in the US market – value frameworks,
the ICER institute and its influence
Patient centricity – the importance of
understanding that the end-user must be the focal point of the
After the course, you will have strengthened your capacity to
understand and deal with crucial market access issues. You will
have learned about key trends in market access and how market
access decisions are made and how the decision frameworks affect
requirements for evidence for new health care interventions. You
Acquired a basic market access vocabulary.
Gained insight into the toolbox of the market access
Gotten an overview of the key challenges of market
Identified the key stakeholders and their influence on the drug
reimbursement and prescription process some of the most important
markets (e.g.: US, UK, Germany and Denmark).
Gained an understanding of payers’ perspective of key markets
and of new reimbursement models which are impacting market
Developed skills that will allow you to generate, apply and
present real world evidence to maximizemarket access
Integrated competencies on how to demonstrate product
The compulsory syllabus comprises a collection of review papers,
textbook chapters and case studies corresponding to approximately
500 pages (extra 200 pages self-selected literature for the
optional term paper).
Teaching and learning methods
The course is organized as an intensive 10-day
course and comprises lectures, group discussions, presentations and
discussions. In order to emphasize the flow of the process, the
course is to a large extent based on the use of cases in both
lectures and assignments.
Applicants must meet the following criteria:
• A relevant bachelor degree or equivalent
• A minimum of 2 years of relevant job experience
• Proficiency in English
The course is for professionals working in the
field of pharmaceuticals. It is intended as continuing professional
development for professionals in the pharmaceutical industry,
particularly in regulatory affairs, medical affairs and sales and
marketing, including decision-makers and administrators in the
public and private sectors. The course offers an excellent
introduction for those less familiar with market access and will
provide a deeper understanding for those with experience within
administration and marketing. Please note, however, that the course
is not an advanced course for market access